<DOC>
	<DOCNO>NCT00003070</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , enalapril , may protect normal cell toxic effect chemotherapy . It know whether enalapril effective placebo treat heart damage patient receive anthracycline chemotherapy childhood cancer . PURPOSE : Randomized double-blinded phase III trial compare effectiveness enalapril placebo treat heart damage patient receive anthracycline chemotherapy childhood cancer .</brief_summary>
	<brief_title>Enalapril Treating Heart Damage Patients Who Received Anthracycline Chemotherapy Childhood Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether enalapril treatment result reduction body surface area-adjusted leave ventricular mass anthracycline-treated survivor childhood cancer . II . Determine whether improvement ventricular function achieve enalapril sustained alters course late cardiotoxicity . III . Determine impact enalapril therapy quality life . OUTLINE : This double blind , placebo control , randomize study . Patients stratify base cumulative anthracycline dose , age cancer diagnosis , duration time since cessation anthracycline therapy . Patients administer enalapril placebo mouth bid . Patients undergo series cardiac test administration drug . Follow-up occur 2 , 6 , 12 month every year thereafter . PROJECTED ACCRUAL : 75 patient treatment arm accrue .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose childhood malignancy prior anthracycline therapy Echocardiographic evidence reduce fractional shortening , reduce contractility , increase afterload , combination At least 6 month oncologic disease free PATIENT CHARACTERISTICS : Age : At least 8 study entry le 22 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : No history renal disease No known renal artery stenosis Cardiovascular : No congenital cardiovascular malformation No active congestive heart failure attributable sepsis renal failure No medication heart condition No history symptomatic arrhythmia antedate anthracycline therapy No constrictive pericarditis No uncontrolled hypertension Pulmonary : No primary valvular outflow tract obstruction Other : Not pregnant lactating Must use adequate contraception No reaction intolerance ACE inhibitor PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 1 year since prior cumulative anthracycline therapy least 200 mg/m2 No prior amsacrine therapy Endocrine therapy : Not specify Radiotherapy : No prior mediastinal , spinal , total body irradiation include heart Surgery : Not specify Other : No concurrent angiotensin convert enzyme ( ACE ) inhibitor treatment No concurrent treatment investigational drug No oncologic therapy within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>